# Mayo Clinic

Source: https://onco.cc/institutions/mayo-clinic/  
OnCo record `mayo-clinic` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Consistently the top-ranked US hospital overall, with strong proton therapy and the first US carbon-ion centre under construction.

## Summary

Mayo Clinic, headquartered in Rochester, Minnesota, is consistently the top-ranked US hospital overall and holds NCI comprehensive designation through the Mayo Clinic Comprehensive Cancer Center, which spans Rochester, Phoenix and Jacksonville; it sits fifth in the Newsweek/Statista oncology ranking. Its cancer strengths are multiple myeloma, lymphoma and individualised medicine, with proton therapy and the first US carbon-ion facility under construction in Jacksonville. OnCo links it to the Atlas pathology model built with Aignostics and Charité, to liver transplantation for cancer, to senescence and JAK-STAT pathway work, and to people including S. Vincent Rajkumar, Shaji K. Kumar and Matthew P. Goetz. Whether carbon-ion therapy earns its cost against protons is the open question its new centre will help answer. The Arizona and Florida campuses have their own OnCo pages.

## Fields

- Kind: Institution
- Last checked: 2026-09-04
- City: Rochester, MN, US
- Type: hospital
- NCI designation: comprehensive
- Website: https://www.mayoclinic.org

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Mayo_Clinic
- Official website: https://www.mayoclinic.org
- PTCOG: particle therapy facilities in operation: https://www.ptcog.site/index.php/facilities-in-operation-public

## Connected records

- technologies: [Atlas (Aignostics, Mayo Clinic, Charité)](https://onco.cc/technologies/atlas-aignostics/), [Carbon-ion therapy](https://onco.cc/technologies/carbon-ion/), [Gamma Knife](https://onco.cc/technologies/gamma-knife/), [Liver transplantation for cancer (Milan criteria and beyond)](https://onco.cc/technologies/liver-transplant-oncology/), [Proton therapy](https://onco.cc/technologies/proton-therapy/), [Proton therapy machines: cyclotrons, synchrotrons and single-room systems](https://onco.cc/technologies/proton-therapy-systems/), [Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS)](https://onco.cc/technologies/radiosurgery-srs/)
- people: [A. Oliver Sartor](https://onco.cc/people/oliver-sartor/), [Cheryl L. Willman](https://onco.cc/people/cheryl-willman/), [Evanthia Galanis](https://onco.cc/people/evanthia-galanis/), [Jan C. Buckner](https://onco.cc/people/jan-buckner/), [Keith C. Bible](https://onco.cc/people/keith-bible/), [Mark R. Litzow](https://onco.cc/people/mark-litzow/), [Matthew P. Goetz](https://onco.cc/people/matthew-goetz/), [Paul D. Brown](https://onco.cc/people/paul-brown/), [S. Vincent Rajkumar](https://onco.cc/people/vincent-rajkumar/), [Shaji K. Kumar](https://onco.cc/people/shaji-kumar/), [Stephen A. Boorjian](https://onco.cc/people/stephen-boorjian/), [Stephen J. Russell](https://onco.cc/people/stephen-russell/), [Tanios Bekaii-Saab](https://onco.cc/people/tanios-bekaii-saab/)
- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- key papers: [Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer](https://onco.cc/key-papers/paper-hu-germline-mutations-pancreatic-cancer-risk-jama-2018/), [Circulating tumor DNA profiling of advanced biliary tract cancers](https://onco.cc/key-papers/paper-mody-biliary-ctdna-profiling-jco-po-2019/), [Identification of Lynch syndrome among patients with colorectal cancer](https://onco.cc/key-papers/paper-moreira-lynch-syndrome-identification-jama-2012/), [Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer](https://onco.cc/key-papers/paper-couch-tnbc-germline-17-genes-jco-2015/), [Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes](https://onco.cc/key-papers/paper-sharma-endpac-model-new-onset-diabetes-gastroenterology-2018/), [Non-V600 BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer](https://onco.cc/key-papers/paper-jones-non-v600-braf-colorectal-jco-2017/), [Probability of pancreatic cancer following diabetes: a population-based study](https://onco.cc/key-papers/paper-chari-pancreatic-cancer-following-diabetes-gastroenterology-2005/), [Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing](https://onco.cc/key-papers/paper-shimelis-tnbc-risk-genes-jnci-2018/), [Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer](https://onco.cc/key-papers/paper-leon-ferre-tils-tnbc-no-chemotherapy-jama-2024/)
- roadmaps: [Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question](https://onco.cc/roadmaps/pancreatic-roadmap/), [Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem](https://onco.cc/roadmaps/tnbc-roadmap/)
- trials: [Gemcitabine, cisplatin and nab-paclitaxel phase 2 (MD Anderson and Mayo)](https://onco.cc/trials/gap-phase2-mdacc/)
- institutions: [Mayo Clinic Comprehensive Cancer Center in Arizona](https://onco.cc/institutions/mayo-clinic-arizona/), [Mayo Clinic Comprehensive Cancer Center in Florida](https://onco.cc/institutions/mayo-clinic-florida/), [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/)
- ideas: [AI that spots pancreatic cancer on scans taken a year before diagnosis](https://onco.cc/ideas/idea-prev-pancreas-ai-prediagnostic-ct/), [New diabetes after 50 plus weight loss triggers a pancreatic cancer check](https://onco.cc/ideas/idea-prev-new-onset-diabetes-pancreas-pathway/), [One-two punch: clear senescent cells after chemotherapy](https://onco.cc/ideas/idea-senolytics-after-chemo/)
- pathways: [Cellular senescence](https://onco.cc/pathways/senescence/), [JAK-STAT signalling](https://onco.cc/pathways/jak-stat/)
- companies: [Aignostics](https://onco.cc/companies/aignostics/), [Hitachi (particle therapy)](https://onco.cc/companies/hitachi/)

---
JSON: https://onco.cc/api/v1/entities/mayo-clinic.json